SCHEMBL2031141

SCHEMBL2031141

Cc1cc(Cl)cc(C)c1-n1cc(N)ccc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 2/20 0.40
ALDH1A1 P00352 5/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37
CYP3A4 P08684 3/20 0.36
ANPEP P15144 1/20 0.33
DPP4 P27487 1/20 0.33
KDM4E B2RXH2 4/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
CASP1 P29466 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
CASP7 P55210 1/20 0.33
CA9 Q16790 1/20 0.33
CYP1A2 P05177 2/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034396 0.80 KDM4E (0.32) ALDH1A1KDM4EHPGDHSD17B10CYP1A2
SCHEMBL2033585 0.78 KDM4E (0.30) ALDH1A1KDM4EHPGDHSD17B10CYP1A2
SCHEMBL27723213 0.77 BRPF1 (0.40) BRPF1ALDH1A1ALOX15HTTATM
SCHEMBL2028119 0.76 RXRA (0.40) ALDH1A1ALOX15KDM4EHSD17B10CA12
SCHEMBL2891894 0.74 TDP1 (0.38) ALDH1A1HTTCYP3A4KDM4EHPGD
SCHEMBL18754936 0.66 SMN1; SMN2 (0.41) BRPF1ALDH1A1CYP3A4ANPEPDPP4
SCHEMBL16475251 0.65 CYP3A4 (0.45) BRPF1ALDH1A1ALOX15HTTATM
SCHEMBL11402688 0.65 SRC (0.37) ALDH1A1HTTATMKDM4ECASP1
SCHEMBL3305181 0.65 ALDH1A1 (0.61) ALDH1A1ALOX15HTTATMKDM4E
SCHEMBL5002060 0.63 KDM4E (0.60) BRPF1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968572-B2 Nitrogen-containing heterocyclic compound and pharmaceutical application thereof ONO PHARMACEUTICALS CO., LTD. (JP) 2011-06-28 US disclosed
US-20100063104-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2010-03-11 US disclosed
EP-1932840-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063104-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF NOS2, NOS1, MAPK1 BRPF1 3211/4885ALDH1A1 1368/4885ALOX15 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.